Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02565732 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Primary Axillary Hyperhidrosis
A Phase 2 study of Hyperhidrosis, sponsored by Revance Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
- 1
- Study location
NCT02565732: Completed Phase 2 study of Hyperhidrosis, sponsored by Revance Therapeutics.
NCT02565732 is a Phase 2 study of Hyperhidrosis that has completed, run by Revance Therapeutics. The registered enrollment target is 67 participants, below the 91-participant average among 8 other Hyperhidrosis trials with a reported enrollment target (26% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02565732, a Phase 2 study of Hyperhidrosis, has completed, sponsored by Revance Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a safety and efficacy study of botulinum toxin type A in subjects with primary axillary hyperhidrosis.
Primary Outcome
Improvement at follow-up in the experimental groups compared to the placebo group
Conditions Studied
Interventions
- BIOLOGICAL Botulinum toxin type A
- BIOLOGICAL Placebo comparator
Study Locations (1)
California
- - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2015-09 |
| Est. Completion | 2016-01 |
| Phase | Phase 2 |
What the finished NCT02565732 record still lists
NCT02565732 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 67 participants, a relatively small participant target, below the 91-participant average among 8 other Hyperhidrosis trials with a reported enrollment target (26% lower).
The record links to 1 condition, with Hyperhidrosis appearing as the primary indexed condition, and to 2 interventions - of which Botulinum toxin type A is the first listed.
NCT02565732 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02565732 about?
NCT02565732 is a clinical study titled "Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Primary Axillary Hyperhidrosis". This is a safety and efficacy study of botulinum toxin type A in subjects with primary axillary hyperhidrosis.
What is the current status of trial NCT02565732?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2015-09. Estimated completion is 2016-01.
What conditions does trial NCT02565732 study?
This clinical trial studies the following conditions: Hyperhidrosis.
What interventions are being tested in trial NCT02565732?
The interventions under investigation include: Botulinum toxin type A (BIOLOGICAL), Placebo comparator (BIOLOGICAL).
Who is sponsoring clinical trial NCT02565732?
This trial is sponsored by Revance Therapeutics, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02565732 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hyperhidrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02565732's enrollment target sits among peer trials
67 5th of 8 higher than 4 of 8 other Hyperhidrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hyperhidrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Efficacy of an Anticholinergic Agent for Treatment of Primary Axillary Hyperhidrosis
COMPLETED · Phase 2
-
A Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis
COMPLETED · Phase 2
-
A Study to Evaluate Clinical Effect, Pharmacokinetics , Safety, and Tolerability of Umeclidinium in Palmar Hyperhidrosis Subjects
COMPLETED · Phase 2
-
An Open Label Study for Palmar Hyperhydrosis
COMPLETED · Phase 2
-
Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary Hyperhidrosis
COMPLETED · Phase 2
-
Botulinum Toxin Therapy in Hidradenitis Suppurativa
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03213002 · 67 participants · Phase 1
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- NCT04115163 · 67 participants · Phase 2
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- NCT04315324 · 67 participants · Phase 1
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT04532424 · 67 participants · NA
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia